Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.

Agustí A. et al, (2023), Respirology

A randomised trial of a T2-composite-biomarker strategy adjusting corticosteroidtreatment in severe asthma, a post- hoc analysis by sex.

Eastwood MC. et al, (2023), The journal of allergy and clinical immunology. In practice

Baseline FeNO Independently Predicts the Dupilumab Response in Patients with Moderate-To-Severe Asthma.

Pavord ID. et al, (2022), The journal of allergy and clinical immunology. In practice

Effectiveness of exhaled nitric oxide for the prediction of non-invasive left atrial pressure in older people: a cross-sectional cohort study

Jones ST. et al, (2022), BJGP Open, BJGPO.2022.0105 - BJGPO.2022.0105

Diagnosis and assessment of the asthmas.

Pavord ID. et al, (2022), The journal of allergy and clinical immunology. In practice

Case-finding and diagnosis of obstructive airway diseases: the Dragons' Den experience.

Pavord ID., (2022), The European respiratory journal, 60

Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy

Chen S. et al, (2022), International Journal of Chronic Obstructive Pulmonary Disease, Volume 17, 2187 - 2200

Sub‐stratification of type‐2 high airway disease for therapeutic decision‐making: A ‘bomb’ (blood eosinophils) meets ‘magnet’ ( FeNO ) framework

Couillard S. et al, (2022), Respirology, 27, 573 - 577

Treatable traits in the NOVELTY study.

Agustí A. et al, (2022), Respirology (Carlton, Vic.)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing.

Couillard S. et al, (2022), Thorax

Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation.

Diver S. et al, (2022), Allergy

Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker‐high and ‐low severe asthma

Khalfaoui L. et al, (2022), Allergy

Exacerbation Profile and Risk Factors in a T2-Low Severe Asthma Population.

McDowell PJ. et al, (2022), American journal of respiratory and critical care medicine

Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling.

Couillard S. et al, (2022), BMJ open, 12

Asthma remission- what is it and how can it be achieved?

Thomas D. et al, (2022), The European respiratory journal

Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study.

Foster J. et al, (2022), BMJ open, 12

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)

Couillard S. et al, (2022), ERJ Open Research, 00570 - 2021

Choosing a Biologic for Patients with Severe Asthma.

Pavord ID. et al, (2021), The journal of allergy and clinical immunology. In practice

Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients

Youngs J. et al, (2021), PLOS Pathogens, 17, e1009804 - e1009804

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil driven diseases

Pavord ID. et al, (2021), Allergy

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?